Quoted references:
1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
2. Getz GS. Thematic review series: the immune system and atherogenesis. Immune function in atherogenesis. J Lipid Res 2005;46:1-10.
3. Bendtzen K. Den inflammatoriske reaktion. In: Hansen NE, Haunsø S, Schaffalitzky de Muckadell OB, editors. Medicinsk kompendium. København/Copenhagen: Nyt Nordisk Forlag Arnold Busck A/S; 2004. p. 59-74.
4. Getz GS. Thematic review series: the immune system and atherogenesis. Bridging the innate and adaptive immune systems. J Lipid Res 2005;46:619-622.
5. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874.
6. Geisler T, Bhatt DL. The role of inflammation in atherothrombosis: current and future strategies of medical treatment. Med Sci Monit 2004;10:RA308-16.
7. Bendtzen K, Hansen PR, Rieneck K, The Spironolactone/Arthritis Study Group. Spironolactone inhibits production of proinflammatory cytokines, including tumor necrosis factor alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 2003;134:151-158.
